Theravance THRX

  1. All
  2. Commentary
  3. Headlines

    Related Topics:

    1. What GSK's Q3 Results Mean For Theravance


      Thu, 23 Oct 2014

      What GSK's Q3 Results Mean For Theravance

    2. Anoro Ellipta beats Spiriva HandiHaler in COPD trial


      Fri, 17 Oct 2014

      Theravance ( THRX -1.8% ) and collaboration partner GlaxoSmithKline's ( GSK +1.7% ) Anoro Ellipta (umeclidinium/vilanterol) improved

    3. Update: Why Theravance Jumped


      Fri, 17 Oct 2014

      By Early Retiree : Yesterday, Theravance (NASDAQ: THRX ) published a press release presenting positive results ..... lung function study comparing the efficacy and safety of Theravance 's Anoro Ellipta (umeclidinium/vilanterol), the

    4. New finance chief at Theravance


      Thu, 9 Oct 2014

      Theravance ( THRX -5.1% ) appoints Eric d'Esparbes as SVP and CFO. He joins the firm from Joule Unlimited where he had similar duties. Post your comment!

    5. Guilty By Association, Theravance Biopharma Is On Sale


      Fri, 3 Oct 2014

      By Early Retiree : Introduction Theravance Biopharma (NASDAQ: TBPH ) was spun off Theravance (NASDAQ: THRX ) in June 2014 and basically is the old THRX minus the rights on three vilanterol-based products: Anoro

    6. From Barron’s, September 29, 2014 (Part 2)


      Sat, 27 Sep 2014

      BABA ; sell puts as options on BABA start to trade on Monday; pg 20]; Apple [ AAPL ; pg 20]. Bearish stories: Theravance [ THRX ; pg 14]; agricultural sector [machinery AGCO, CNHI, DE ; fertilizer AGU, CF, MOS, POT ; seeds/chemicals

    7. From Barron’s, July 28, 2014 (Part 2)


      Sat, 26 Jul 2014

      even become a SIFI ; its bank has had the top 5-yr CD rate for months ; pg 13]; Dow Chemical [ DOW ; pg 16]; Theravance [ THRX ; COPD drug royalty based company after the spinoff of R&D arm TBPH ; it sells COPD drugs through GSK ; pg 18

    8. FDA panel votes in favor of approval of Glaxo lung drug Anoro


      Tue, 10 Sep 2013

      WASHINGTON, Sept 10 (Reuters) - An federal advisory panel has recommended that the U.S. Food and Drug Administration approve a drug made by GlaxoSmithKline Plc and Theravance Inc to treat chronic...

    9. Safety data on Glaxo COPD drug inconclusive -FDA staff


      Fri, 6 Sep 2013

      Sept 6 (Reuters) - An experimental drug to treat chronic obstructive pulmonary disease made by GlaxoSmithKline Plc and Theravance Inc appears to work, but its safety data are not entirely conclusive,...

    10. Elan Transformation Continues, but We Remain Skeptical of Deal Values


      Mon, 20 May 2013

      proposed new business deals, and we're maintaining our fair value estimate as we digest the news in relation to last week's Theravance deal announcement. We're intrigued by Elan's decision to take a page out of Valeant's playbook, focusing on underpenetrated

    « Prev12345Next »
    Content Partners